A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies

A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies

Objective: Nivolumab has been used for treating non-small cell lung cancer (NSCLC) worldwide. Whether neutrophil-lymphocyte ratio (NLR) can predict the prognosis of NSCLC treated with Nivolumab is still under debate. This meta-analysis was to assess the significance of NLR as a predictive factor in...

Full description

Bibliographic Details
Main Authors: Dedong Cao, Huilin Xu, Ximing Xu, Tao Guo, Wei Ge
Format: Article
Language:English
Published: Taylor & Francis Group 2018-11-01
Series:OncoImmunology
Subjects:
neutrophil-to-lymphocyte ratio
nivolumab
immunotherapy
lung cancer
meta-analysis
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1507262

Internet

http://dx.doi.org/10.1080/2162402X.2018.1507262

Similar Items